General
Preferred name
BRIVANIB
Synonyms
BMS-540215 ()
Brivanib (BMS-540215) ()
BMS 540215 ()
cpd 12 ()
P&D ID
PD003474
CAS
649735-46-6
Tags
available
drug candidate
probe
Drug indication
Liver cancer
Breast cancer
Drug Status
investigational
Max Phase
Phase 3
Probe info
Probe type
experimental probe
Probe sources
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Brivanib (BMS-540215) is a potent ATP-competitive inhibitor of VEGFR2. Its discovery is reported in .
The International Non-proprietary Name (INN) brivanib alaninate has PubChem CID 11154925, and this represents the prodrug used in clinical trials.
DESCRIPTION Brivanib (BMS-540215) is a potent ATP-competitive inhibitor of VEGFR2. Its discovery is reported in .
The International Non-proprietary Name (INN) brivanib alaninate has PubChem CID 11154925, and this represents the prodrug used in clinical trials. (GtoPdb)
MOA Inhibitor, ATP competitive (Chemical Probes.org)
DESCRIPTION inhibitor of VEGFR 1/2 (Informer Set)
Cell lines
1
Organisms
0
Compound Sets
18
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Chemical Probes.org
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
External IDs
28
Properties
(calculated by RDKit )
Molecular Weight
370.14
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
4
cLogP
3.52
TPSA
84.67
Fraction CSP3
0.26
Chiral centers
1.0
Largest ring
6.0
QED
0.56
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
FLT1
KDR
CYP3A4, FGFR1, FLT1, KCNH2, KDR
VEGFR inhibitor
VEGFR
FGFR,VEGFR
Compound status
clinical
MOA
FGFR inhibitor, VEGFR inhibitor
Orthogonal probe
Cabozantinib
Target class
Protein kinase
Kinase
Pathway
Autophagy
Protein Tyrosine Kinase/RTK
Target subclass
TK
Source data